Health ❯ Healthcare

Obesity

Treatment Options Weight Management Weight Loss Weight Loss Treatments Treatment Weight Loss Drugs Obesity Treatment Medications Obesity Management Health Risks

Wearable Data Show People Move Less After Starting GLP‑1 Weight‑Loss Drugs

ENDO 2026 presentations link the activity drop to greater risk of lean muscle loss and call for prescribing structured exercise with GLP‑1 therapy.

Stories older than 24h

MHRA Approves Wegovy Daily Pill for Weight Loss in UK

AstraZeneca’s Oral GLP‑1 Elecoglipron Delivers Strong Phase 2 Weight and Blood‑Sugar Results

Major U.S. Societies Publish First Clinical Guideline for Cardiovascular‑Kidney‑Metabolic Syndrome

Semaglutide Shows Early Promise for Restoring Fertility in PMOS

Employers and Insurers Pull Back Coverage for GLP‑1 Weight‑Loss Drugs

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

Veru Rally Follows Novo Nordisk Deal to Supply Wegovy for Phase 2b Trial

Penn Study Finds About 30% Lower Breast Cancer Incidence Among Women Prescribed GLP‑1 Drugs

UAE Becomes First Country Outside U.S. to Offer Wegovy Pill

GLP‑1 Drugs Reshape Obesity Care as Surgery Delivers Larger, More Durable Weight Loss

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

Oral GLP‑1 Approval and New Trials Push Weight‑Loss Drugs Into Mass Market

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

New Trials Show Daily Pills Can Help Maintain Weight Loss After GLP-1 Injections

GLP-1 Drugs Linked to Lower Death and Recurrence in Breast Cancer, Large Study Finds

New Analyses Find Weight-Loss Surgery Outperforms GLP-1 Drugs as Prescriptions Soar

French Drug Regulator Fines Novo Nordisk and Eli Lilly Over Obesity Drug Promotions

Ashley Graham Condemns GLP-1 Weight-Loss Trend as a 'Smack in the Face'